SLGL - ソル・ゲル・テクノロジ―ズ (Sol-Gel Technologies Ltd.) ソル・ゲル・テクノロジ―ズ

 SLGLのチャート


 SLGLの企業情報

symbol SLGL
会社名 Sol-Gel Technologies Ltd (ソル・ゲル・テクノロジ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins sirs-t and vered. The Company is designed its proprietary silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert inorganic silica shell which creates an unnoticeable barrier between the active ingredient and the skin.   ソル・ゲル・テクノロジ―ズはイスラエルの製薬企業。独自のマイクロカプセル化技術プラットフォ―ムに基づき、皮膚用医薬品の開発と製品化を行う。臨床試験第2段階を完了した主力製品候補には、膿ほう性ロザケア(酒さ)の治療薬VEREDや、尋常性挫創の治療薬TWINおよびSIRS-Tがある。同社はまた、その他の皮膚用ジェネリック医薬品の開発も手掛ける。   Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for the development of Twyneo, under investigation for the treatment of acne vulgaris, and Epsolay, under investigation for the treatment of inflammatory lesions of rosacea. The Company's pipeline also includes SGT-210 (erlotinib gel), under investigation for the treatment of palmoplantar keratoderma, and three pre-clinical assets - erlotinib, tapinarof and roflumilast - currently being tested for various pharmaceutical indications.
本社所在地 Weizmann Science Park 7 Golda Meir Street Ness Ziona 7403650 ISR
代表者氏名 Alon Seri-Levy アロン・セリ・レヴィ
代表者役職名 Chief Executive Officer Co-Founder Director
電話番号 +972 8-931-3433
設立年月日 35704
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数
url www.sol-gel.com
nasdaq_url https://www.nasdaq.com/symbol/slgl
adr_tso
EBITDA EBITDA(百万ドル) -32.72400
終値(lastsale) 7.2
時価総額(marketcap) 136439769.6
時価総額 時価総額(百万ドル) 115.21580
売上高 売上高(百万ドル) 0.08100
企業価値(EV) 企業価値(EV)(百万ドル) ー
当期純利益 当期純利益(百万ドル) -32.35600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Sol Gel Technologies Ltd revenues decreased from $0K to -$93K. Net loss increased 7% to $12.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research_Development Expense increase of 12% to $10.5M (expense) GENERAL AND ADMINISTRATIVE EXPENSES increase of 8% to $2.7M (expense).

 SLGLのテクニカル分析


 SLGLのニュース

   Sol-Gel Technologies to Participate in the 2022 Jefferies Global Healthcare Conference  2022/06/01 12:00:00 GlobeNewswire
NESS ZIONA, Israel, June 01, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, today announced that Chief Executive Officer, Alon Seri-Levy, will present a corporate update at the 2022 Jefferies Global Healthcare Conference to be held June 8 -10, 2022 in-person, in New York, NY.
   Sol-Gel Technologies to Present in Upcoming H.C. Wainwright Global Investment Conference  2022/05/17 11:00:00 GlobeNewswire
NESS ZIONA, Israel, May 17, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, today announced that that the Company will present at the upcoming H.C. Wainwright Global Investment Conference being held May 23-26, 2022.
   Sol-Gel Technologies GAAP EPS of -$0.18 beats by $0.11 (NASDAQ:SLGL)  2022/05/13 11:57:05 Seeking Alpha
Sol-Gel Technologies press release (SLGL): Q1 GAAP EPS of -$0.18 beats by $0.11.As of March 31, 2022, Sol-Gel had $30.2 million in cash, cash equivalents and deposits, and $6.1…
   Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update  2022/05/13 11:00:00 GlobeNewswire
NESS ZIONA, Israel, May 13, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today financial results for the first quarter ended March 31, 2022 and provided a corporate update.
   Sol-Gel''s stock rises as FDA approves Epsolay to treat skin condition rosacea  2022/04/25 11:37:11 Seeking Alpha
The Food and Drug Administration ((FDA)) approved Sol-Gel Technologies (SLGL) Epsolay, a proprietary cream formulation of benzoyl peroxide 5%, to treat inflammatory lesions of rosacea…
   Head to Head Contrast: Ascendis Pharma A/S (NASDAQ:ASND) versus Sol-Gel Technologies (NASDAQ:SLGL)  2021/12/03 08:52:42 ETF Daily News
Ascendis Pharma A/S (NASDAQ:ASND) and Sol-Gel Technologies (NASDAQ:SLGL) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings. Profitability This table compares Ascendis Pharma A/S and Sol-Gel Technologies net margins, return on equity [] The post Head to Head Contrast: Ascendis Pharma A/S (NASDAQ:ASND) versus Sol-Gel Technologies (NASDAQ:SLGL) appeared first on ETF Daily News .
   Sol-Gel Technologies (NASDAQ:SLGL) Price Target Lowered to $19.00 at HC Wainwright  2021/11/16 11:20:42 Dakota Financial News
Sol-Gel Technologies (NASDAQ:SLGL) had its target price lowered by HC Wainwright from $21.00 to $19.00 in a research note published on Monday morning, PriceTargets.com reports. HC Wainwright currently has a buy rating on the stock. Several other research firms also recently issued reports on SLGL. BMO Capital Markets reissued a buy rating and issued a []
   Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Expected to Post Earnings of -$0.28 Per Share  2021/11/13 19:10:42 Transcript Daily
Brokerages expect Sol-Gel Technologies Ltd. (NASDAQ:SLGL) to announce earnings per share of ($0.28) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Sol-Gel Technologies earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.42). Sol-Gel Technologies reported earnings per share of ($0.36) []
   Sol-Gel Technologies (NASDAQ:SLGL) Price Target Cut to $21.00 by Analysts at Raymond James  2021/11/12 13:16:44 Dakota Financial News
Sol-Gel Technologies (NASDAQ:SLGL) had its price target reduced by equities research analysts at Raymond James from $23.00 to $21.00 in a research note issued on Friday, Benzinga reports. The firm presently has a strong-buy rating on the stock. Raymond James target price indicates a potential upside of 131.28% from the stocks current price. A number []
   Sol-Gel Technologies EPS beats by $0.12, beats on revenue  2021/11/11 12:25:34 Seeking Alpha
   Head to Head Contrast: Ascendis Pharma A/S (NASDAQ:ASND) versus Sol-Gel Technologies (NASDAQ:SLGL)  2021/12/03 08:52:42 ETF Daily News
Ascendis Pharma A/S (NASDAQ:ASND) and Sol-Gel Technologies (NASDAQ:SLGL) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings. Profitability This table compares Ascendis Pharma A/S and Sol-Gel Technologies net margins, return on equity [] The post Head to Head Contrast: Ascendis Pharma A/S (NASDAQ:ASND) versus Sol-Gel Technologies (NASDAQ:SLGL) appeared first on ETF Daily News .
   Sol-Gel Technologies (NASDAQ:SLGL) Price Target Lowered to $19.00 at HC Wainwright  2021/11/16 11:20:42 Dakota Financial News
Sol-Gel Technologies (NASDAQ:SLGL) had its target price lowered by HC Wainwright from $21.00 to $19.00 in a research note published on Monday morning, PriceTargets.com reports. HC Wainwright currently has a buy rating on the stock. Several other research firms also recently issued reports on SLGL. BMO Capital Markets reissued a buy rating and issued a []
   Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Expected to Post Earnings of -$0.28 Per Share  2021/11/13 19:10:42 Transcript Daily
Brokerages expect Sol-Gel Technologies Ltd. (NASDAQ:SLGL) to announce earnings per share of ($0.28) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Sol-Gel Technologies earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.42). Sol-Gel Technologies reported earnings per share of ($0.36) []
   Sol-Gel Technologies (NASDAQ:SLGL) Price Target Cut to $21.00 by Analysts at Raymond James  2021/11/12 13:16:44 Dakota Financial News
Sol-Gel Technologies (NASDAQ:SLGL) had its price target reduced by equities research analysts at Raymond James from $23.00 to $21.00 in a research note issued on Friday, Benzinga reports. The firm presently has a strong-buy rating on the stock. Raymond James target price indicates a potential upside of 131.28% from the stocks current price. A number []
   Sol-Gel Technologies EPS beats by $0.12, beats on revenue  2021/11/11 12:25:34 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ソル・ゲル・テクノロジ―ズ SLGL Sol-Gel Technologies Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)